Publishing research using ab124918? Please let us know so that we can cite the reference in this datasheet.
ab124918 has been referenced in 5 publications.
Ando K et al.Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.Oncotarget 8:43733-43751 (2017).
Lohse I et al.Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.PLoS One 11:e0167272 (2016).
Hollingworth R et al.Activation of DNA Damage Response Pathways during Lytic Replication of KSHV.Viruses 7:2908-27 (2015).
Sowd GA et al.SV40 utilizes ATM kinase activity to prevent non-homologous end joining of broken viral DNA replication products.PLoS Pathog 10:e1004536 (2014).
Juvekar A et al.Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.Cancer Discov 2:1048-63 (2012).
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Get resources and offers direct to your inboxSign up